Bristol-Myers Comments on Nulojix Trials

Bristol-Myers Squibb Company (NYSE: BMY) today announced new 4-year resultsfrom the long-term extensions (LTE) of the BENEFIT and BENEFIT-EXT clinicaltrials of NULOJIX® (belatacept), the first selective T-cell costimulationblocker indicated for the prophylaxis of organ rejection in adult Epstein-BarrVirus (EBV) seropositive patients receiving a kidney transplant, incombination with basiliximab induction, mycophenolate mofetil (MMF), andcorticosteroids. Results showed that the safety profile of NULOJIX throughyear 4 was consistent compared with results at year 3 with no new safetysignals being identified, and that the renal function benefit versuscyclosporine was maintained through 4 years in patients enrolled in the LTEfrom both the BENEFIT and BENEFIT-EXT trials. The new data were presented inoral sessions at the 2012 American Transplant Congress (ATC) in Boston.